Cargando…
A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy
BACKGROUND: Neck pain, sensory disturbance and motor dysfunction in most patients suffered cervical spondylotic myelopathy (CSM). However, some conservative treatments are limited by their modest effectiveness. In the other hand, surgical treatment is necessary when symptoms are refractory to conser...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437772/ https://www.ncbi.nlm.nih.gov/pubmed/32872078 http://dx.doi.org/10.1097/MD.0000000000021776 |
_version_ | 1783572685022822400 |
---|---|
author | Xu, Chongqing Zhou, Xiaoning Tong, Zhengyi Ma, Junming Ye, Jie Xu, Jinhai Mo, Wen |
author_facet | Xu, Chongqing Zhou, Xiaoning Tong, Zhengyi Ma, Junming Ye, Jie Xu, Jinhai Mo, Wen |
author_sort | Xu, Chongqing |
collection | PubMed |
description | BACKGROUND: Neck pain, sensory disturbance and motor dysfunction in most patients suffered cervical spondylotic myelopathy (CSM). However, some conservative treatments are limited by their modest effectiveness. In the other hand, surgical treatment is necessary when symptoms are refractory to conservative treatments and neurological function of the patients has deteriorated. Many patients use complementary and alternative medicine, including traditional Chinese medicine, to address their symptoms. The purpose of the present study is to examine effectiveness and safety of Yiqi-Huayu-Tongsui (YQHYTS) granule, a compound traditional Chinese herbal medicine, on symptoms in patients with mild or moderate CSM. METHODS/DESIGN: A randomized, double blinded, placebo-controlled clinical trial to evaluate the efficacy and safety of YQHYTS granule is proposed. 72 patients in Longhua Hospital with the diagnosis of mild or moderate CSM will be randomly allocated into 2 groups, and treated with YQHYTS granule or placebo. The prescription of the trial drugs (YQHYTS granule/placebo) is 20 grams twice a day for 3 months. The primary outcome measurements include visual analog scale, Japanese Orthopedic Association, and Neck Disability Index score. The secondary outcome measurements are electromyogram and Pfirrmann classification. DISCUSSION: YQHYTS granule has been established and applied in Longhua Hospital for many years. As it has a potential benefit in treating mild or moderate CSM, we designed a double-blind, prospective, randomized controlled trial and would like to publish the results and conclusions later. If YQHYTS granule can alleviate neck pain, sensory disturbance, and even motor dysfunction without adverse effects, it may be a unique strategy for the treatment of mild or moderate CSM. TRIAL REGISTRATION: Chinese Clinical Trial Registry ID: ChiCTR1900028192. Registered 15 December 2019, Available at: http://www.chictr.org.cn/edit.aspx?pid=46913&htm=4 |
format | Online Article Text |
id | pubmed-7437772 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-74377722020-09-02 A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy Xu, Chongqing Zhou, Xiaoning Tong, Zhengyi Ma, Junming Ye, Jie Xu, Jinhai Mo, Wen Medicine (Baltimore) 3700 BACKGROUND: Neck pain, sensory disturbance and motor dysfunction in most patients suffered cervical spondylotic myelopathy (CSM). However, some conservative treatments are limited by their modest effectiveness. In the other hand, surgical treatment is necessary when symptoms are refractory to conservative treatments and neurological function of the patients has deteriorated. Many patients use complementary and alternative medicine, including traditional Chinese medicine, to address their symptoms. The purpose of the present study is to examine effectiveness and safety of Yiqi-Huayu-Tongsui (YQHYTS) granule, a compound traditional Chinese herbal medicine, on symptoms in patients with mild or moderate CSM. METHODS/DESIGN: A randomized, double blinded, placebo-controlled clinical trial to evaluate the efficacy and safety of YQHYTS granule is proposed. 72 patients in Longhua Hospital with the diagnosis of mild or moderate CSM will be randomly allocated into 2 groups, and treated with YQHYTS granule or placebo. The prescription of the trial drugs (YQHYTS granule/placebo) is 20 grams twice a day for 3 months. The primary outcome measurements include visual analog scale, Japanese Orthopedic Association, and Neck Disability Index score. The secondary outcome measurements are electromyogram and Pfirrmann classification. DISCUSSION: YQHYTS granule has been established and applied in Longhua Hospital for many years. As it has a potential benefit in treating mild or moderate CSM, we designed a double-blind, prospective, randomized controlled trial and would like to publish the results and conclusions later. If YQHYTS granule can alleviate neck pain, sensory disturbance, and even motor dysfunction without adverse effects, it may be a unique strategy for the treatment of mild or moderate CSM. TRIAL REGISTRATION: Chinese Clinical Trial Registry ID: ChiCTR1900028192. Registered 15 December 2019, Available at: http://www.chictr.org.cn/edit.aspx?pid=46913&htm=4 Lippincott Williams & Wilkins 2020-08-14 /pmc/articles/PMC7437772/ /pubmed/32872078 http://dx.doi.org/10.1097/MD.0000000000021776 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 3700 Xu, Chongqing Zhou, Xiaoning Tong, Zhengyi Ma, Junming Ye, Jie Xu, Jinhai Mo, Wen A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy |
title | A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy |
title_full | A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy |
title_fullStr | A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy |
title_full_unstemmed | A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy |
title_short | A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy |
title_sort | randomized, double-blind, placebo-controlled trial for yi-qi hua-yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy |
topic | 3700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437772/ https://www.ncbi.nlm.nih.gov/pubmed/32872078 http://dx.doi.org/10.1097/MD.0000000000021776 |
work_keys_str_mv | AT xuchongqing arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT zhouxiaoning arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT tongzhengyi arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT majunming arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT yejie arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT xujinhai arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT mowen arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT xuchongqing randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT zhouxiaoning randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT tongzhengyi randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT majunming randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT yejie randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT xujinhai randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy AT mowen randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy |